



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/86, 15/45, C07K 14/135, 14/115, A61K 31/70	A1	(11) International Publication Number: WO 99/25858 (43) International Publication Date: 27 May 1999 (27.05.99)
(21) International Application Number: PCT/CA98/01064 (22) International Filing Date: 13 November 1998 (13.11.98) (30) Priority Data: 60/065,791 14 November 1997 (14.11.97) US (71) Applicant (for all designated States except US): CONNAUGHT LABORATORIES LIMITED [CA/CA]; 1755 Steeles Avenue West, North York, Ontario M2R 3T4 (CA). (72) Inventors; and (75) Inventors/Applicants (for US only): PARRINGTON, Mark [CA/CA]; 45 Martin Street, Bradford, Ontario L3Z 1Z4 (CA). LI, Xiaomao [CN/CA]; 106 Glenmanor Way, Thornhill, Ontario L4J 3E5 (CA). (74) Agent: STEWART, Michael, I.; 6th floor, 330 University Avenue, Toronto, Ontario M5G 1R7 (CA).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: ALPHAVIRUS VECTORS FOR PARAMYXOVIRUS VACCINES (57) Abstract <p>A DNA vector comprises a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus DNA genome replication regions, and a second DNA sequence encoding a paramyxovirus protein, particularly a respiratory syncytial virus fusion (RSV F) protein or a RSV F protein fragment that generates antibodies that specifically react with RSV F protein, the first and second DNA sequences being under the transcriptional control of a promoter, preferably a cytomegalovirus promoter, which may include Intron A. Such vectors also contain a further nucleotide sequence located between the promoter sequence and the alphavirus sequence to enhance the immunoprotective ability of the RSV F protein when expressed <i>in vivo</i>. Such DNA vectors may be used to immunize a host against disease caused by infection with RSV or other paramyxovirus, including a human host, by administration thereto, and may be formulated as immunogenic compositions with pharmaceutically-acceptable carriers for such purposes. Such vectors also may be used to produce antibodies for detection of RSV or other paramyxovirus infection in a sample.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TITLE OF INVENTIONALPHAVIRUS VECTORS FOR PARAMYXOVIRUS VACCINES

5

FIELD OF INVENTION

The present invention relates to the field of paramyxoviridae vaccines and is particularly concerned with vaccines comprising DNA encoding the fusion (F) protein of respiratory syncytial virus (RSV) in an alphavirus vector.

BACKGROUND OF THE INVENTION

Human respiratory syncytial virus (RSV) has been identified as a major pathogen responsible for severe respiratory tract infections in infants, young children and the institutionalized elderly (refs. 1,2,3,4 - throughout this application, various references are cited in parentheses to describe more fully the state of the art to which this invention pertains. Full bibliographic information for each citation is found at the end of the specification, immediately preceding the claims. The disclosures of these references are hereby incorporated by reference into the present disclosure). Global mortality and morbidity figures indicate that there is an urgent need for an efficacious RSV vaccine (refs. 5,6). In the USA alone, approximately 100,000 children are hospitalized annually with severe cases of pneumonia and bronchiolitis resulting from an RSV infection. Inpatient and ambulatory care for children with RSV infections has been estimated to cost in excess of \$340 million each year in the USA. The World Health Organization (WHO) and the National Institute of Allergy and Infectious Disease (NIAID) vaccine advisory

committees have ranked RSV second only to HIV for vaccine development. Both the annual morbidity and mortality figures as well as the staggering health care costs for managing RSV infections have provided the incentive for aggressively pursuing the development of efficacious RSV vaccines. However, such a vaccine is still not available.

Formalin-inactivated (FI-RSV) and live attenuated RSV vaccines have failed to demonstrate efficacy in clinical trials (refs. 7,8,9,10). Moreover, the formalin-inactivated RSV vaccine caused enhanced disease in some children following exposure to wild-type RSV (refs. 7,8,9,10). Elucidation of the mechanism(s) involved in the potentiation of RSV disease is important for the design of safe RSV vaccines, especially for the seronegative population. Recent experimental evidence suggests that an imbalance in cell-mediated responses may contribute to immunopotential. Enhanced histopathology observed in mice that were immunized with the FI-RSV and challenged with virus could be abrogated by depletion of CD4+ cells or both interleukin-4 (IL-4) and IL-10.

The RSV fusion (F) glycoprotein is one of the major immunogenic proteins of the virus. This envelope glycoprotein mediates both fusion of the virus to the host cell membrane and cell-to-cell spread of the virus (ref. 1). The F protein is synthesized as a precursor (F_0) molecule which is proteolytically cleaved to form a disulphide-linked dimer composed of the N-terminal F_2 and C-terminal F_1 moieties (ref. 11). The amino acid sequence of the F protein is highly conserved among RSV

subgroups A and B and is a cross-protective antigen (refs. 6,12). In the baculovirus expression system, a truncated secreted version of the RSV F protein has been expressed in *Trichoplusia ni* insect cells (ref. 13). The recombinant protein was demonstrated to be protective in the cotton rats (ref. 13).

Studies on the development of live viral vaccines and glycoprotein subunit vaccines against parainfluenza virus infection are being pursued. Clinical trial results with a formalin-inactivated PIV types 1,2,3 vaccine demonstrated that this vaccine was not efficacious (refs. 14, 15, 16). Further development of chemically-inactivated vaccines was discontinued after clinical trials with a formalin-inactivated RSV vaccine demonstrated that not only was the vaccine not effective in preventing RSV infection but many of the vaccinees who later become infected with RSV suffered a more serious disease. Most of parainfluenza vaccine research has focused on candidate PIV-3 vaccines (ref. 17) with significantly less work being reported for PIV-1 and PIV-2. Recent approaches to PIV-3 vaccines have included the use of the closely related bovine parainfluenza virus type 3 and the generation of attenuated viruses by cold-adaptation of the virus (refs. 18, 19, 20, 21).

Another approach to parainfluenza virus type 3 vaccine development is a subunit approach focusing on the surface glycoproteins hemagglutinin-neuraminidase (HN) and the fusion (F) protein (refs. 22, 23, 24). The HN antigen, a typical type II glycoprotein, exhibits both haemagglutination and neuraminidase activities and

is responsible for the attachment of the virus to sialic acid containing host cell receptors. The type I F glycoprotein mediates fusion of the viral envelope with the cell membrane as well as cell to cell spread of the virus. It has recently been demonstrated that both the HN and F glycoproteins are required for membrane fusion. The F glycoprotein is synthesized as an inactive precursor (F) which is proteolytically cleaved into disulfide-linked F2 and F1 moieties. While the HN and F proteins of PIV-1, -2 and -3 are structurally similar, they are antigenically distinct. Neutralizing antibodies against the HN and F proteins of one of PIV type are not cross-protective. Thus, an effective PIV subunit vaccine must contain the HN and F glycoproteins from the three different types of parainfluenza viruses. Antibody to either glycoprotein is neutralizing in vitro. A direct correlation has been observed between the level of neutralizing antibody titres and resistance to PIV-3 infections in infants. Native subunit vaccines for parainfluenza virus type 3 have investigated the protectiveness of the two surface glycoproteins. Typically, the glycoproteins are extracted from virus using non-ionic detergents and further purified using lectin affinity or immunoaffinity chromatographic methods. However, neither of these techniques may be entirely suitable for large scale production of vaccines under all circumstances. In small animal protection models (hamsters and cotton rats), immunization with the glycoproteins was demonstrated to prevent infection with live PIV-3 (refs. 25, 26, 27, 28, 29).

The HN and F glycoproteins of PIV-3 have also been produced using recombinant DNA technology. HN and F glycoproteins have been produced in insect cells using the baculovirus expression system and by use of vaccinia virus and adenovirus recombinants (refs. 30, 31, 32, 33, 34). In the baculovirus expression system, both full-length and truncated forms of the PIV-3 glycoproteins as well as a chimeric F-HN fusion protein have been expressed. The recombinant proteins have been demonstrated to be protective in small animal models (see WO91/00104, US Application No. 07/773,949 filed November 29, 1991, assigned to the assignee hereof).

Semliki Forest virus (SFV) is a member of the Alphavirus genus in the Togaviridae family. The mature virus particle contains a single copy of a ssRNA genome with a positive polarity that is 5'-capped and 3'-polyadenylated. It functions as an mRNA and naked RNA can start an infection when introduced into cells. Upon infection/transfection, the 5' two-thirds of the genome is translated into a polyprotein that is processed into the four nonstructural proteins (nsP1 to 4) by self cleavage. Once the ns proteins have been synthesized they are responsible for replicating the plus-strand (42S) genome into full-length minus strands (ref. 14). These minus-strands then serve as templates for the synthesis of new plus-strand (42S) genomes and the 26S subgenomic mRNA (ref. 14). This subgenomic mRNA, which is colinear with the last one-third of the genome, encodes the SFV structural proteins.

In 1991 Liljestrom and Garoff (ref. 15) designed a series of expression vectors based on the SFV cDNA

replicon. These vectors had the virus structural protein genes deleted to make the way for heterologous inserts, but preserved the nonstructural coding region for production of the nsP1 to 4 replicase complex.

5 Short 5' and 3' sequence elements required for RNA replication were also preserved. A polylinker site was inserted downstream from the 26S promoter followed by translation stop sites in all three frames. An SpeI site was inserted just after the 3' end of the SFV cDNA
10 for linearization of the plasmid for use in vitro transcription reactions.

Injection of SFV RNA encoding a heterologous protein have been shown to result in the expression of the foreign protein and the induction of antibody in a
15 number of studies (refs. 16,17). The use of SFV RNA inoculation to express foreign proteins for the purpose of immunization would have several of the advantages associated with plasmid DNA immunization. For example, SFV RNA encoding a viral antigen may be introduced in
20 the presence of antibody to that virus without a loss in potency due to neutralization by antibodies to the virus. Also, because the protein is expressed in vivo the protein should have the same conformation as the protein expressed by the virus itself. Therefore,
25 concerns about conformational changes which could occur during protein purification leading to a loss in immunogenicity, protective epitopes and possibly immunopotential, could be avoided by plasmid DNA immunization.

30 In copending US Patent Application No. 08/476,397 filed June 7, 1995, assigned to the assignee hereof and

the disclosure of which is incorporated herein by reference (WO96/040945), there is described reference the use of plasmid vectors containing RSV F protein-encoding DNA for DNA immunization against RSV infection.

5 In copending United States Patent Application No. 08/896,500 filed July 18, 1997, assigned to the assignee hereof and the disclosure of which is incorporated herein by reference, there is described the use of plasmid vectors containing RSV G protein-encoding DNA
10 for DNA immunization against RSV infection.

In my copending United States Patent Application No. 08/923,558, filed September 4, 1997, assigned to the assignee hereof and the disclosure of which is incorporated by reference, I describe a DNA vector using
15 an alphavirus vector, including Semliki Forest virus vector, containing a DNA sequence encoding a paramyxovirus protein, specifically RSV-F, for making an RNA transcript for immunization.

In WO95/27044, the disclosure of which is
20 incorporated herein by reference, there is described the use of alphavirus cDNA vectors based on cDNA complementary to the alphavirus RNA sequence. Once transcribed from the cDNA under transcriptional control of a heterologous promoter, the alphavirus RNA is able
25 to self-replicate by means of its own replicase and thereby amplify the copy number of the transcribed recombinant RNA molecules.

Infection with RSV leads to serious disease. It would be useful and desirable to provide improved
30 vectors for in vivo administration of immunogenic preparations, including vaccines, for protection against

disease caused by RSV and other paramyxoviruses. In particular, it would be desirable to provide vaccines that are immunogenic and protective in humans, including seronegative infants, that do not cause disease enhancement (immunopotentialiation).

SUMMARY OF THE INVENTION

The present invention provides novel immunogenic materials and immunization procedures based on such novel materials for immunizing against disease caused by respiratory syncytial virus. In particular, the present invention is directed towards the provision of DNA vaccines against disease caused by infection with paramyxoviridae.

In accordance with one aspect of the present invention, there is provided a vector, comprising a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus RNA genome replication regions to permit *in vivo* replication; a second DNA sequence encoding a paramyxovirus protein or a protein fragment that generates antibodies that specifically react with the paramyxovirus protein, the second DNA sequence being inserted into a region of the first DNA sequence which is non-essential for replication; the first and second DNA sequences being under transcriptional control of a promoter; and a third DNA sequence located adjacent the second DNA sequence to enhance the immunoprotective ability of the paramyxovirus protein when expressed *in vivo* from the vector in a host.

The paramyxovirus protein may be selected from the group consisting of a parainfluenza virus (PIV) and a respiratory syncytial virus (RSV). The PIV protein may be from PIV-1, PIV-2, PIV-3 or PIV-4, particularly the HN and F glycoproteins of PIV-3. The RSV protein particularly may be the F or G glycoprotein of RSV.

The second DNA sequence may encode a full length RSV F protein, or may encode a RSV F protein lacking the transmembrane anchor and cytoplasmic tail. The lack of the coding region for the transmembrane anchor and cytoplasmic tail results in a secreted form of the RSV F protein. Alternatively, as described in the aforementioned U.S. Patent Application 08/896,500, the second DNA sequence may encode the full-length RSV-G protein or a truncated RSV G protein lacking a transmembrane region, resulting in a secreted form of the protein.

The alphavirus preferably is a Semliki Forest virus and the first DNA sequence is the Semliki Forest viral sequence contained in plasmid pSFVI.

The third nucleotide sequence may comprise a pair of splice sites to prevent aberrant mRNA splicing, *in vivo*, whereby substantially all transcribed mRNA from the vector upon administration encodes the RSV protein. Such third nucleotide sequence is preferably located between the first nucleotide sequence and the promoter sequence. Such third nucleotide sequence may be that of rabbit β -globin intron II, as shown in Figure 8 of copending U.S. Patent Application No. 08/476,397 (WO 96/040945).

The promoter sequence may be an immediate early cytomegalovirus (CMV) promoter. The human cytomegalovirus Intron A sequence may be provided downstream of the promoter and upstream of the third
5 nucleotide sequence.

A vector encoding the F protein and provided in accordance with one embodiment of the invention may be specifically pMP44, having the identifying characteristics shown in Figure 1D.

10 The vectors provided herein may be used to immunize a host against RSV infection or disease by *in vivo* expression of RSV F protein or RSV G protein, which may lack a transmembrane region, or other paramyxovirus protein, following administration of the vectors. In
15 accordance with a further aspect of the present invention, therefore, there is provided a method of immunizing a host against disease caused by infection with respiratory syncytial virus or other paramyxovirus, which comprises administering to the host an effective
20 amount of a vector provided herein.

The present invention also includes a novel method of using a gene encoding an RSV F or G protein or a fragment of an RSV or G protein capable of generating antibodies which specifically react with RSV F or G
25 protein to protect a host against disease caused by infection with respiratory syncytial virus, which comprises isolating the gene; operatively linking said gene to a DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the
30 complement of complete alphavirus RNA genome replication regions in a region of said DNA sequence which is non-

essential for replication to form a vector wherein said gene and DNA sequence are under transcriptional control of a promoter; operatively linking the gene to an immunoprotection enhancing sequence to produce an enhanced immunoprotection by the RSV F or G protein in the host, preferably by introducing the immunoprotection enhancing sequence between the control sequence and the alphavirus sequence; and introducing the vector into the host. A corresponding procedure may be used for other paramyxoviridae.

In addition, the present invention includes a method of producing a vaccine for protection of a host against disease caused by infection with respiratory syncytial virus (RSV), which comprises isolating a first DNA sequence encoding an RSV or G protein, from which the transmembrane anchor and cytoplasmic tail may be absent; operatively linking said first DNA sequence to a second DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complete alphavirus genome replication regions in a region of said second DNA sequence which is non-essential for replication to form a vector wherein said first and second DNA sequences are under transcriptional control of a promoter; operatively linking the first nucleotide sequence to a third nucleotide sequence to enhance the immunoprotective ability of the RSV F or G protein when expressed *in vivo* from the vector in a host; and formulating the vector as a vaccine for *in vivo* administration. A corresponding procedure may be used for other paramyxoviridae.

The present invention further includes a vaccine for administration to a host, including a human host, produced by the method as well as immunogenic compositions comprising an immunoeffective amount of the
5 vectors described herein.

BRIEF DESCRIPTION OF DRAWINGS

Figures 1A to 1B show a schematic of a procedure of assembly of vector pMP44;

Figures 2A to 2B show a schematic of a procedure of
10 assembly of vector pMP44;

Figures 3A to 3E contain the nucleotide sequence of plasmid pMP44 (SEQ ID NO:1);

Figure 4 shows the anti-RSV F titres in sera from mice taken 4 weeks after priming and 2 weeks after
15 boosting;

Figure 5 shows the nucleotide sequence for a synthetic oligonucleotide coding for the hepatitis delta ribozyme (SEQ ID no; 2,3); and

Figures 6A to 6C show the nucleotide sequence for
20 the SFV EcoRV-SpeI fragment ligated to the ribozyme of Figure 5 (SEQ ID no: 4).

GENERAL DESCRIPTION OF INVENTION

As described above, the present invention, in general, relates to protection of hosts against disease caused by infection by paramyxovirus by DNA immunization using DNA vectors. In particular, the invention is concerned with protection of hosts against disease caused by infection by respiratory syncytial virus (RSV), although not specifically limited thereto. The description which follows refers specifically to employing DNA sequences encoding RSV F or G protein and fragments thereof which generate antibodies which specifically react with RSV F or G protein.

In this application, the terms "RSV F protein" and "RSV G protein" are used to define a full-length RSV F or G protein, including proteins having variations in their amino acid sequences including those naturally occurring in various strain of RSV and those introduced by PCR amplification of the encoding gene while retaining the immunogenic properties, a secreted form of the RSV F or G protein lacking a transmembrane anchor and cytoplasmic tail, as well as fragments capable of generating antibodies which specifically react with RSV F or G protein and functional analogs. In this application, a first protein is a "functional analog" of a second protein if the first protein is immunologically related to and/or has the same function as the second protein. The functional analog may be, for example, a fragment of the protein or a substitution, addition or deletion mutant thereof.

A vector is constructed to contain a first DNA sequence which is complementary to at least part of an

alphavirus RNA genome, specifically Semliki Forest virus, and having the complement of complete alphavirus RNA genome replication regions to permit replication in vivo. A second DNA sequence encoding the RSV F or G protein is inserted into a region of the first DNA sequence which is non-essential for replication. The first and second DNA sequences are under transcriptional control of a promoter to permit expression of the RSV protein in a host immunized with the vector.

10 The promoter sequence may be the immediately early cytomegalovirus (CMV) promoter. This promoter is described in ref. 36. Any other convenient promoter may be used, including constitutive promoters, such as, Rous Sarcoma Virus LTRs, and inducible promoters, such as
15 metallothioneine promoter, and tissue specific promoters.

The recombinant vector may include a third nucleotide sequence located adjacent the alphavirus sequence to enhance the immunoprotective ability of the RSV F or G protein when expressed in vivo in a host.
20 Such enhancement may be provided by increased in vivo expression, for example, by increased mRNA stability, enhanced transcription and/or translation. This additional sequence preferably is located between the promoter sequence and the alphavirus sequence.

25 This enhancement sequence may comprise a pair of splice sites to prevent aberrant mRNA splicing during transcription so that substantially all transcribed mRNA is intact alphavirus RNA encoding a gene of interest, for example, an RSV F protein. Specifically, rabbit β -
30 globin Intron II sequence may provide such splice sites, as also described in ref. 37.

Additional enhancement may be obtained by, including an additional DNA sequence between the promoter and the enhancer sequence. Such additional DNA sequence may comprise the immediate early
5 cytomagalovirus Intron A sequence.

The vectors provided herein, when administered to an animal, effect *in vivo* RSV F protein expression, as demonstrated by an antibody response in the animal to which it is administered and the conferring of
10 protection. As may be seen from the results detailed in the Examples below, the DNA vectors produced a high anti-F IgG antibody titre and confer protection.

In comparison to the vectors described in the aforementioned U.S. Patent Application nos. 08/476,397
15 and 08/896,500, the vectors described herein provide a protective immune response using a lower dose and less time. In comparison to the vectors described in the aforementioned U.S. Patent Application nos. 08/923,558, 08/896,550 and 08/476,397 using native RSV F, the
20 vectors described herein produce protective immune response in the absence of pretreatment of the animal model with cardiotoxin, a material known to increase the uptake of DNA and enhance the immune response.

The vector provided herein may also comprise a
25 fourth nucleotide sequence encoding a further antigen from RSV, an antigen from at least one other pathogen or at least one immunomodulating agent, such as cytokine. Such vector may contain said fourth nucleotide sequence in a chimeric or a bicistronic structure. Alternatively,
30 vectors containing the fourth nucleotide sequence may be

separately constructed and coadministered to a host, with the DNA vector provided herein.

In addition, there may be provided at the 3'-end of the Simliki Forest virus segment, a hepatitis delta virus-ribosyme sequence to ensure proper *in vivo* cleavage at the 3'-end of the Simliki Forest virus sequence. Any other convenient sequence may be employed to achieve this effect.

It is clearly apparent to one skilled in the art, that the various embodiments of the present invention have many applications in the fields of vaccination, diagnosis and treatment of RSV infections. A further non-limiting discussion of such uses is further presented below.

1. Vaccine Preparation and Use

Immunogenic compositions, suitable to be used as vaccines, may be prepared from the RSV F or RSV G genes and other paramyxovirus genes and vectors as disclosed herein. The vaccine elicits an immune response in a subject which includes the production of anti-F or anti-G antibodies. Immunogenic compositions, including vaccines, containing the DNA vector may be prepared as injectables, in physiologically-acceptable liquid solutions or emulsions for polynucleotide administration. The nucleic acid may be associated with liposomes, such as lecithin liposomes or other liposomes known in the art, as a nucleic acid liposome (for example, as described in WO 93/24640, ref. 38) or the DNA vector may be associated with an adjuvant, as described in more detail below. Liposomes comprising cationic lipids interact spontaneously and rapidly with

polyanions such as DNA and RNA, resulting in liposome/nucleic acid complexes that capture up to 100% of the polynucleotide. In addition, the polycationic complexes fuse with cell membranes, resulting in an intracellular delivery of polynucleotide that bypasses the degradative enzymes of the lysosomal compartment. Published PCT application WO 94/27435 describes compositions for genetic immunization comprising cationic lipids and polynucleotides. Agents which assist in the cellular uptake of nucleic acid, such as calcium ions, viral proteins and other transfection facilitating agents, may advantageously be used.

Polynucleotide immunogenic preparations may also be formulated as microcapsules, including biodegradable time-release particles. Thus, U.S. Patent 5,151,264 describes a particulate carrier of a phospholipid/glycolipid/polysaccharide nature that has been termed Bio Vecteurs Supra Moléculaires (BVSM). The particulate carriers are intended to transport a variety of molecules having biological activity in one of the layers thereof.

U.S. Patent 5,075,109 describes encapsulation of the antigens trinitrophenylated keyhole limpet hemocyanin and staphylococcal enterotoxin B in 50:50 poly (DL-lactide-co-glycolide). Other polymers for encapsulation are suggested, such as poly(glycolide), poly(DL-lactide-co-glycolide), copolyoxalates, polycaprolactone, poly(lactide-co-caprolactone), poly(esteramides), polyorthoesters and poly(8-hydroxybutyric acid), and polyanhydrides.

Published PCT application WO 91/06282 describes a delivery vehicle comprising a plurality of bioadhesive microspheres and antigens. The microspheres being of starch, gelatin, dextran, collagen or albumin. This delivery vehicle is particularly intended for the uptake of vaccine across the nasal mucosa. The delivery vehicle may additionally contain an absorption enhancer.

The RSV F or G genes and vectors may be mixed with pharmaceutically acceptable excipients which are compatible therewith. Such excipients may include, water, saline, dextrose, glycerol, ethanol, and combinations thereof. The immunogenic compositions and vaccines may further contain auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, or adjuvants to enhance the effectiveness thereof. Immunogenic compositions and vaccines may be administered parenterally, by injection subcutaneously, intravenously, intradermally or intramuscularly, possibly following pretreatment of the injection site with a local anaesthetic. Alternatively, the immunogenic compositions formed according to the present invention, may be formulated and delivered in a manner to evoke an immune response at mucosal surfaces. Thus, the immunogenic composition may be administered to mucosal surfaces by, for example, the nasal or oral (intragastic) routes. Alternatively, other modes of administration including suppositories and oral formulations may be desirable. For suppositories, binders and carriers may include, for example, polyalkalene glycols or triglycerides. Oral formulations may include normally employed incipients,

such as, for example, pharmaceutical grades of saccharine, cellulose and magnesium carbonate.

The immunogenic preparations and vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective, protective and immunogenic. The quantity to be administered depends on the subject to be treated, including, for example, the capacity of the individual's immune system to synthesize the RSV F protein and antibodies thereto, and if needed, to produce a cell-mediated immune response. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner. However, suitable dosage ranges are readily determinable by one skilled in the art and may be of the order of about 1 μ g to about 1 mg of the RSV F or G genes and vectors. Suitable regimes for initial administration and booster doses are also variable, but may include an initial administration followed by subsequent administrations. The dosage may also depend on the route of administration and will vary according to the size of the host. A vaccine which protects against only one pathogen is a monovalent vaccine. Vaccines which contain antigenic material of several pathogens are combined vaccines and also belong to the present invention. Such combined vaccines contain, for example, material from various pathogens or from various strains of the same pathogen, or from combinations of various pathogens.

In particular embodiments of the present invention, the vector comprising a first nucleotide sequence

encoding an F or G protein of RSV may be delivered in conjunction with a targeting molecule to target the vector to selected cells including cells of the immune system.

5 The DNA vectors may be delivered to the host by a variety of procedures, for example, Tang et al. (ref. 39) disclosed that introduction of gold microprojectiles coated with DNA encoding bovine growth hormone (BGH) into the skin of mice resulted in production of anti-BGH
10 antibodies in the mice, while Furth et al. (ref. 40) showed that a jet injector could be used to transfect skin, muscle, fat and mammary tissues of living animals.

2. Immunoassays

The RSV F or G genes and vectors of the present
15 invention are useful as immunogens for the generation of anti-F or anti-G antibodies for use in immunoassays, including enzyme-linked immunosorbent assays (ELISA), RIAs and other non-enzyme linked antibody binding assays or procedures known in the art. In ELISA assays, the
20 vector first is administered to a host to generate antibodies specific to the RSV F or G protein or other paramyxovirus protein. These RSV F- or G-specific antibodies are immobilized onto a selected surface, for example, a surface capable of binding the antibodies,
25 such as the wells of a polystyrene microtiter plate. After washing to remove incompletely adsorbed antibodies, a nonspecific protein such as a solution of bovine serum albumin (BSA) that is known to be antigenically neutral with regard to the test sample may
30 be bound to the selected surface. This allows for blocking of nonspecific adsorption sites on the

immobilizing surface and thus reduces the background caused by nonspecific bindings of antisera onto the surface.

The immobilizing surface is then contacted with a sample, such as clinical or biological materials, to be tested in a manner conducive to immune complex (antigen/antibody) formation. This procedure may include diluting the sample with diluents, such as solutions of BSA, bovine gamma globulin (BGG) and/or phosphate buffered saline (PBS)/Tween. The sample is then allowed to incubate for from about 2 to 4 hours, at temperatures such as of the order of about 20° to 37°C. Following incubation, the sample-contacted surface is washed to remove non-immunocomplexed material. The washing procedure may include washing with a solution, such as PBS/Tween or a borate buffer. Following formation of specific immunocomplexes between the test sample and the bound RSV F specific antibodies, and subsequent washing, the occurrence, and even amount, of immunocomplex formation may be determined.

Biological Deposits

Certain vectors that contain the gene encoding RSV F protein and referred to herein have been deposited with the American Type Culture Collection (ATCC) located at 10801 University Boulevard, Manassas, VA 20110-2209, U.S.A., pursuant to the Budapest Treaty and prior to the filing of this application.

Samples of the deposited plasmids will become available to the public upon grant of a patent based upon this United States patent application and all restrictions on access to the deposits will be removed

22

at that time. Non-viable deposits will be replaced.

The invention described and claimed herein is not to be limited in scope by plasmids deposited, since the deposited embodiment is intended only as an illustration of the invention. Any equivalent or similar plasmids that encode similar or equivalent antigens as described in this application are within the scope of this invention.

Deposit Summary

<u>Plasmid</u>	<u>ATCC Designation</u>	<u>Date Deposited</u>
pMP37	97905	Feb. 27, 1997
pMP42		

EXAMPLES

The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific Examples. These Examples are described solely for purposes of illustration and are not intended to limit the scope of the invention. Changes in form and substitution of equivalents are contemplated as circumstances may suggest or render expedient. Although specific terms have been employed herein, such terms are intended in a descriptive sense and not for purposes of limitations.

Methods of molecular genetics, protein biochemistry and immunology used but not explicitly described in this disclosure and these Examples are amply reported in the scientific literature and are well within the ability of those skilled in the art.

30

EXAMPLE 1

This Example describes a scheme for construction of a Semliki Forest Virus (SFV) DNA expression vector containing a truncated RSV F gene as outlined in Figures 1A to 1B.

Plasmid VR1012 was restricted with PstI and then made blunt-ended with T4 DNA polymerase. The β -globin Intron II was excised out of vector pSG5 (Stratagene) and ligated into plasmid VR1012 to generate plasmid pIIE. Plasmid pIIE was then restricted with SalI and EcoRV and ligated to a PCR fragment having the nucleotide sequence:

TCGACATGGCGGATGTGTGACATACACGACGCCAAAAGATTTTGTTCAGCT
CCTGCCACCTCCGCTACGCGAGAGATTAACCACCCACGATGGCCGCCAAAGT
GCATGTTGATATTGAGGCTGACAGCCCATTTCATCAAGTCTTTGCAGAAGGCA
TTTCCGTCGTTTCGAGGTGGAGTCATTGCAGGTCACACCAAATGACCATGCAA
ATGCCAGAGCATTTTTCGCACCTGGCTACCAAATTGATCGAGCAGGAGACTGA
CAAAGACACACTCATCTTGGAT (SEQ ID no: 7) generated from
pSFVI with primers SAL-SFV having the nucleotide
sequence 5'-TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no:
5) and ECO-SFV having the nucleotide sequence 5'-
TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no: 6). The
resulting plasmid pMP38 was then restricted with EcoRV
and BamHI and then dephosphorylated. Plasmid pSFV1
link (see copending application no. _____ (b/o
1038-766)) was then restricted with SpeI and ligated to
the hepatitis delta ribozyme (Fig. 5, SEQ ID nos: 2 and
3). The ligation reaction was then restricted with
EcoRV to release most of the SFV-RSVF plus ribozyme
fragment. This fragment was then ligated to
EcoRV/BamHI restricted pMP38 to produce pMP41.

Example 2

This Example describes an alternative scheme for constructing plasmid pMp44 as outlined in Figure 2.

Plasmid VR1012 was restricted with PstI and then
5 made blunt-ended with T4 DNA polymerase. The β -globin
Intron II was excised out of vector pSG5 (Stratagene)
and ligated into plasmid VR1012 to generate plasmid
pIIE. Plasmid pIIE was then restricted with SalI and
EcoRV and ligated to a PCR fragment having the
10 nucleotide sequence:

```
TCGACATGGCGGATGTGTGACATACACGACGCCAAAAGATTTTGTTCAGCT
CCTGCCACCTCCGCTACGCGAGAGATTAACCACCCACGATGGCCGCCAAAGT
GCATGTTGATATTGAGGCTGACAGCCCATTTCATCAAGTCTTTGCAGAAGGCA
TTTCCGTCGTTTCGAGGTGGAGTCATTGCAGGTCACACCAAATGACCATGCAA
15 ATGCCAGAGCATTTTCGCACCTGGCTACCAAATTGATCGAGCAGGAGACTGA
CAAAGACACACTCATCTTGGAT (SEQ ID no: 7) generated from
pSFVI with primers SAL-SFV having the nucleotide
sequence 5'-TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no:
5) and ECO-SFV having the nucleotide sequence 5'-
20 TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no: 6). The
resulting plasmid pMP38 was then restricted with EcoRV
and BamHI and then dephosphorylated. Plasmid pSFV1
link (see copending application no. _____ (b/o
1038-766)) was then restricted with SpeI and ligated to
25 the hepatitis delta ribozyme (Fig. 5, SEQ ID nos: 2 and
3).
```

The ligation reaction product was then restricted
with EcoRV to release the SFV replicon plus the
ribozyme having the nucleotide sequence as outlines in
30 Figures 6A to 6C. This fragment was then ligated to
the EcoRV/BamHI restricted pMP38 to produce pMP42. The

25

RSV F gene fragment was released from pMP37 by restriction with BamHI, and this fragment was ligated into the BamHI site of pMP42 to produce pMP44. The nucleotide sequence of pMP44 is shown in Figures 3A to 3E.

EXAMPLE 3

This Example describes the immunization of mice with pMP44 and the immunogenicity results obtained.

BALB/C mice were immunized with plasmid pMP44 by the intramuscular (i.m.) route. The anterior tibialts muscles of six BALB/C mice were bilaterally injected with 2 x 100 μ g of plasmid pMP44. This amount is equivalent to approximately 94 μ g of a conventional vector, based on copy number. These mice were boosted in an identical manner 4 weeks later. The control group was immunized with 2 x 25 μ g of SFV-RSV F RNA as described in my aforementioned United States Application No. 08/923,558, except that the muscles were not pre-treated with cardiotoxin. The immunization protocol is set forth in the following Table I:

Table 1 Immunization protocol

Group	Prime	Route of Inoculation	Boost	Route of Inoculation
25	1 SFV-RSVF RNA ¹	Intramuscular	SFV-RSVF RNA ¹	Intramuscular
	2 pMP44 DNA ²	Intramuscular	pMP44DNA ²	Intramuscular

Mice were inoculated with:

1. 25 μ g of RNA was injected into each hind leg muscle in 50 μ L of PBS
2. 100 μ g of DNA was injected into each hind leg muscle in 50 μ L of PBS

Sera was obtained from the mice at 4 and 6 weeks. Anti-RSV F antibody titres (IgG) in these sera were determined by enzyme-linked immunosorbent assay (ELISA), as described in Example 3.

5 The anti-RSV F IgG antibody response in the sera of the BALB/C mice are summarized in Figure 4. The mice immunized with the DNA construct, pMP44, had higher anti-F titres than the mice immunized with the SFV-RSV F RNA.

10 Two weeks after the second immunization, mice were challenged intranasally with 10^6 plaque forming units (pfu) of the A1 strain of RSV (BG-4A). Animals were sacrificed 4 days later. Lungs were aseptically removed, weighed, and homogenized in 2 mL of complete
15 culture medium. The virus titre in lung homogenates was determined in duplicate using vero cells, as previously described (ref. 41).

As seen in Table 2 below, immunization of mice with pMP44 DNA protected mice (5/6) against live RSV
20 challenge, in contrast to the lack of protection when immunization with SFV-RSV F RNA was effected. This result contrasts with the complete protection which is obtained using SFV-RSV F RNA as described in U.S. Patent Application Nos. 08/923,558, 08/476,397 and
25 08/896,500 where the results show protection after pretreatment with cardiotoxin.

Table 2

Group	Immunogen		Mean Virus Lung Titre	
	Prime	Boost	(log10/g±s.d)	% Protection
1	SFV-RSVF RNA	SFV-RSVF RNA	4.26	0
2	pMP44 DNA	pMP44DNA	2.12*	83

* Limit of detection = 1.8

EXAMPLE 4

This Example describes the determination of anti-
5. RSV F antibody titres.

Nunc-MaxiSorp plate wells were coated overnight at room temperature with 2.5 ng of immunoaffinity-purified RSV F protein diluted in 0.05M carbonate-bicarbonate buffer, pH 9.6. Wells were blocked for non-specific
10 binding by adding 0.1% BSA in PBS for 30 min. at room temperature, followed by two washes in a washing buffer of 0.1% BSA in PBS + 0.1% Tween 20. Serial two or four-fold dilutions of mouse serum was added to the wells. After a one hour incubation at room
15 temperature, plates were washed five times with washing buffer, and horseradish peroxidase (HRP) labeled conjugate was added at the appropriate optimal dilution in washing buffer. The total IgG assay used F(ab')₂ goat antimouse IgG (H+L specific)- HRP from Jackson
20 Immuno Research Laboratory Inc. (Baltimore, MD, USA). Sheep anti-mouse IgG1-HRP from Serotec (Toronto, Ontario, Canada) was used in the IgG1 assay and goat anti-mouse IgG2a from Caltag Laboratories (San Francisco, CA, USA) was used in the IgG2a assay.
25 Following one hour incubation at room temperature, the plates were washed five times with washing buffer, and hydrogen peroxide (substrate) in the presence of tetramethylbenzidine was added. The reaction was stopped by adding 2 M sulfuric acid. The colour was
30 read in a Multiscan Titertek plate reader at an optical density (OD) of 450 nm. The titre was taken as the reciprocal of the last dilution at which the OD was

approximately double. This OD must be greater than the negative control of the assay at the starting dilution. The pre-immune serum of each animal was used as the negative control.

5 SUMMARY OF THE DISCLOSURE

In summary of this disclosure, the present invention provides certain novel alphavirus derived DNA vectors containing genes encoding RSV F or RSV G proteins, or other paramyxovirus proteins, methods of
10 immunization using such vectors and methods of diagnosis using such vectors. Modifications are possible within the scope of this invention.

REFERENCES

1. McIntosh K. and Chanock R.M. in Fields B.N. and Knipe D.M. (eds). Virology. Raven Press, New York, 1990, pp.1045-1072.
2. Murphy B.R., Hall S.L., Kulkarni A.B., Crowe J.E., Collins P.L., Connors M., Karron R.A. and Chanock R.M., Virus Res 32, 13-36, 1994.
3. Osterweil D. and Norman D., Am Geriat Soc 36, 659-662, 1990.
4. Agius G., Dindinand G., Biggar R.J., Peyre R., Vaillant V., Ranger S., Poupet J.Y., Cisse M.F. and Casters M., J Med Virol 30, 117-127, 1990.
5. Katz S.L. in New vaccine development establishing priorities Vol 1. National Academic Press, Washington, 1985, pp. 3974 09.
6. Wertz G.W. and Sullender W.M., Biotechnology 20, 151-176, 1992 .
7. Fulginiti V.A., Eller J.J., Sieber O.F., Joyner J.W., Minamitani M. and Meiklejohn G., Am J Epidemiol 89, 449-463, 1969.
8. Chin J., Magoffin R.L., Shearer I.A., Schieble J.H. and Lennette E.H., Am J Epidemiol 89, 449-463, 1969.
9. Belshe R.B., Van Voris L.P. and Mufson M.A., J Infect Dis 145, 311-319, 1982.
10. Kim R.M., Arrobio J.O., Pyles G., Brandt C.D., Camargo E., Chanock R.M. and Parrott R.H., Pediatrics 48, 745-755, 1971.
11. Gruber C. and Levine S., J Gen Virol 64, 825-832, 1983.
12. Olmstead R.A., Elango N. and Prince G.A., Proc Natl Acad Sci USA 83, 7462-7466, 1991.

13. Parrington M., Cockle S., Wyde P., Du R.-P., Snell E., Yan W.-Y., Wang Q., Gisonni L., Sanhueza S., Ewasyshyn M. and Klein M., *Virus Genes* 14, 65-74, 1997
- 5 14. Fulginiti, V.A., Eller, J.J., Sieber, O.F., Joyner, J.W., Minamitani, M. and Meiklejohn, G. (1969) *Am. J. Epidemiol.* 89 (4), 435-448.
- 10 15. Chin, J., Magoffin, R.L., Shearer, L.A., Schieble, J.H. and Lennette, E.H. (1969) *Am. J. Epidemiol.* 89 (4), 449-463.
- 15 16. Jensen, K.E., Peeler, B.E. and Dulworth, W.G. (1962) *J. Immunol.* 89, 216-226.
- 20 17. Murphy, B.R., Prince, G.A., Collins, P.L., Van Wyke-Coelingh, K., Olmsted, R.A., Spriggs, M.K., Parrott, R.H., Kim, H.-Y., Brandt, C.D. and Chanock, R.M. (1988) *Vir. Res.* 11, 1-15.
- 25 18. Hall, S.L., Sarris, C.M., Tierney, E.L., London, W.T., and Murphy, B.R. (1993) *J. Infect. Dis.* 167, 958-962.
- 30 19. Belshe, R.B., Karron, R.A., Newman, F.K., Anderson, E.L., Nugent, S.L., Steinhoff, M., Clements, M.L., Wilson, M.H., Hall, S.L., Tierney, E.L. and Murphy, B.R. (1992) *J. Clin. Microbiol.* 30 (8), 2064-2070.
- 20 20. Hall, S.L., Stokes, A., Tierney, E.L., London, W.T., Belshe, R.B., Newman, F.C. and Murphy, B.R. (1992) *Vir. Res.* 22, 173-184.
- 35 21. Van Wyke Coelingh, K.L., Winter, C.C., Tierney, E.L., London, W.T. and Murphy, B.R. (1988) *J. Infect. Dis.* 157 (4), 655-662.
- 40 22. Ray, R., Novak, M., Duncan, J.D., Matsuoka, Y. and Compans, R.W. (1993) *J. Infect. Dis.* 167, 752-755.
23. Ray, R., Brown, V.E. and Compans, R.W. (1985) *J. Infect. Dis.* 152 (6), 1219-1230.
- 45 24. Ray, R. and Compans, R.W. (1987) *J. Gen. Virol.* 68, 409-418.

25. Ray, R., Glaze, B.J., Moldoveanu, Z. and Compans, R.W. (1988) J. Infect. Dis. 157 (4), 648-654.
- 5 26. Ray, R., Matsuoka, Y., Burnett, T.L., Glaze, B.J. and Compans, R.W. (1990) J. Infect. Dis. 162, 746-749.
- 10 27. Ray, R., Glaze, B.J. and Compans, R.W. (1988) J. Virol. 62 (3), 783-787.
28. Ewasyshyn, M., Caplan, B., Bonneau A.-M., Scollard, N., Graham, S., Usman, S. and Klein, M. (1992) Vaccine 10 (6), 412-420.
- 15 29. Ambrose, M.W., Wyde, P.R., Ewasyshyn, M., Bonneau, A.-M., Caplan, B., Meyer, H.L. and Klein, M. (1991) Vaccine 9, 505-511.
- 20 30. Kasel, J.A., Frank, A.L., Keitel, W.H., Taber, L.H., Glezen W.P. J. Virol. 1984; 52:828-32.
31. Lehman, D.J., Roof, L.L., Brideau, R.J., Aeed, P.A., Thomsen, D.R., Elhammer, A.P., Wathen, M.W. and Homa, F.L. (1993) J. Gen. Virol. 74, 459-469.
- 25 32. Brideau, R.J., Oien, N.L., Lehman, D.J., Homa, F.L. and Wathen, M.W. (1993) J. Gen. Virol. 74, 471-477.
- 30 33. Ebata, S.N., Prevec, L., Graham, F.L. and Dimock, K. (1992) Vir. Res. 24, 21-33.
34. Hall, S.L., Murphy, B.R. and Van Wyke Coelingh, K.L. (1991) Vaccine 9, 659-667.
- 35 35. Strauss E.G. and Strauss J.H., in Schlesinger S.S. and Schlesinger M.i. (eds). The Togaviridae and Flaviviridae. Plenum Press, New York, 1986, pp.35-90.
- 40 36. Chapman, B.S.; Thayer, R.M.; Vincent, K.A. and Haigwood, N.L., Nucl. Acids. Res. 1991, 19: 3979-3986.
- 45 37. Breathnack, R. and Harris, B.A., Nucl. Acids Res. 1983, 11: 7119-7136

38. Nabel, G.J. 1993, Proc. Natl. Acad. Sci. USA 90:
11307-11311.
- 5 39. Tang et al., Nature 1992, 356: 152-154
40. Furth et al., Analytical Biochemistry, 1992, 205:
365-368
41. Prince, G.A. et al, Am. J. Pathol. 93, 771 to 790,
10 1978.

CLAIMS

What we claim is:

1. A vector, comprising:

5 a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus RNA genome replication regions to permit *in vivo* replication; and
a second DNA sequence encoding a paramyxovirus
10 protein or a protein fragment that generates antibodies that specifically react with the paramyxovirus protein, the second DNA sequence being inserted into a region of the first DNA sequence which is non-essential for replication, the first and second DNA sequences being
15 under transcriptional control of a promoter.

2. The vector of claim 1 wherein the paramyxovirus protein is selected from the group consisting of a parainfluenza virus (PIV) and a respiratory syncytial
20 virus (RSV).

3. The vector of claim 2 wherein the PIV protein is selected from the group consisting of PIV-1, PIV-2, PIV-3 and PIV-4
25

4. The vector of claim 3 wherein said PIV protein is selected from the group consisting of the HN and F glycoproteins of PIV-3.

5. The vector of claim 4 wherein the RSV protein is selected from the group consisting of the F or G glycoprotein of RSV.

5 -- 6. The vector of claim 1 wherein the second DNA sequence encodes a full length RSV F or RSV G proteins.

7. The vector of claim 1, wherein the second nucleotide sequence encodes a truncated RSV F or RSV G
10 protein lacking the transmembrane anchor and cytoplasmic tail.

8. The vector of claim 1 wherein the alphavirus is a Semliki Forest virus.

15

9. The vector of claim 1 wherein the first DNA sequence is the Semliki Forest viral sequence contained in plasmid pSFVI.

20 10. The vector of claim 1 wherein the promoter sequence is an immediate early cytomegalovirus (CMV) promoter.

11. The vector of claim 1 further comprising a third DNA sequence located adjacent the second DNA sequence
25 to enhance the immunoprotective ability of the paramyxovirus protein when expressed *in vivo* from the vector in a host.

12. The vector of claim 11 wherein the third nucleotide
30 sequence comprises a pair of splice sites to prevent aberrant mRNA splicing, *in vivo* whereby substantially

35

all transcribed mRNA from the vector region
administration encodes the RSV protein.

13. The vector of claim 12 wherein the third nucleotide
5 sequence is located between the first nucleotide
sequence and the promoter sequence.

14. The vector of claim 13 wherein said third
nucleotide sequence is that of rabbit β -globin intron
10 II.

15. The vector of claim 10 wherein said promoter
sequence is an immediate early cytomegalovirus (CMV)
promoter and the human cytomegalovirus Intron A
15 sequence is provided downstream of the promoter and
upstream of the third nucleotide sequence.

16. The vector of claim 15 further comprising a fourth
nucleotide sequence at the 3'-end of the first
20 nucleotide sequence to ensure proper *in vivo* cleavage
at the 3'-end of the first nucleotide sequence.

17. The vector of claim 16 wherein said fourth
nucleotide sequence is a hepatitis delta virus ribozyme
25 sequence.

18. The vector of claim 1 which has the identifying
characteristics of plasmid pMP44 shown in Figure 2D.

30 19. The vector of claim 1 which has SEQ ID No: 1.

20. A method of immunizing a host against disease caused by infection with paramyxovirus, which comprises administering to the host an effective amount of a vector as claimed in claim 1.

5.

21. The method of claim 21 wherein said vector has the identifying characteristics of plasmid pMP44 shown in Figure 2D.

10 22. The method of claim 21 wherein said vector has SEQ ID no: 1.

23. A method of using a gene encoding an RSV F or G protein or a fragment of an RSV or G protein capable of
15 generating antibodies which specifically react with RSV F or G protein to protect a host against disease caused by infection with respiratory syncytial virus, which comprises:

isolating said gene;

20 operatively linking said gene to a DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus RNA genome replication regions in a region of said DNA sequence which is non-essential for replication
25 to form a vector wherein said gene and DNA sequence are under transcriptional control of a promoter; and
introducing the vector into the host.

24. The method of claim 23 wherein said gene encoding
30 an RSV F protein encodes an RSV F protein lacking the transmembrane region.

25. The method of claim 24 wherein said promoter comprises the immediate early cytomegalovirus promoter.

5 26. The method of claim 25 including the step of:

operatively linking said gene to an immunoprotective enhancing sequence to produce an enhanced immunoprotection to said RSV F protein in said host.

10

27. The method of claim 26 wherein said immunoprotective enhancing sequence is introduced into said vector between said control sequence and said gene.

15 28. The method of claim 27 wherein said immunoprotection enhancing sequence comprises a pair of splice sites to prevent aberrant mRNA splicing whereby substantially intact transcribed mRNA encodes an RSV F protein.

20

29. The method of claim 28 wherein said immunoprotection enhancing sequence is that of rabbit β -globin intron II.

25 30. The method of claim 23 wherein said vector is plasmid pMP44.

31. The vector of claim 23 wherein said vector has SEQ ID no: 1.

30

32. A method of producing a vaccine for protection of a host against disease caused by infection with respiratory syncytial virus (RSV), which comprises:

isolating a first DNA sequence encoding an RSV or G protein, from which the transmembrane anchor and cytoplasmic tail may be absent;

operatively linking said first DNA sequence to a second DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complete alphavirus genome replication regions in a region of said second DNA sequence which is non-essential for replication to form a vector wherein said first and second DNA sequences are under transcriptional control of a promoter; and

formulating the vector as a vaccine for *in vivo* administration.

33. The composition of claim 32 wherein said vector has the identifying characteristics of pMP44 shown in Figure 2D.

34. The method of claim 32 wherein said vector has SEQ ID no: 1.

35. A vaccine for administration to a host, including a human host, produced by the method of claim 32.

36. An immunogenic composition comprising an immunoeffective amount of a vector of claim 1.

39

37. The composition of claim 36 wherein said vector has the identifying characteristic of pMP44 in Figure 2D.

38. The composition of claim 36 wherein said vector has

5 -- SEQ ID-no: 1.

1/16

Figure 4 Construction of pMP44⁴¹




Fig. 4a 1a

2/16





Fig 1B

3/16



+ Bam HI fragments
from pMP37



Ligate



Fig 1c

4/16




FIG 10

5/16


Figure 1 Construction of pMP44

fig. 2A

6/16




Fig. 2A

Figure 2 Nucleotide sequence of plasmid pMP44

```

tcgcgcgttt cggatgatgac ggtgaaaacc tctgacacat gcagctcccg gagacgggtca 60
cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcgggtg 120
ttggcgggtg tcggggctgg cttaactatg cgcatcaga gcagattgta ctgagagtgc 180
accatattcg gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcagattgg 240
ctattgcca ttgcatacgt tgtatccata tcataatatg tacatttata ttggtcatg 300
tccaacatta ccgcatgtt gacattgatt attgactagt tattaatagt aatcaattac 360
ggggtcatta gttcatagcc catatatgga gttccgcgtt acataactta cggtaaattg 420
cccgctggc tgaccgcca acgaccccg cccattgacg tcaataatga cgtatgttcc 480
catagtaacg ccaataggga ctttccattg acgtcaatgg gtggagtatt tacggtaaac 540
tgcccacttg gcagtacatc aagtgtatca tatgccaaat acgcccccta ttgacgtcaa 600
tgacggtaaa tggccgcctt ggcattatgc ccagtacatg accttatggy actttcctac 660
ttggcagtag atctacgtat tagtcatcgc tattaccatg gtgatgcggt tttggcagta 720
catcaatggg cgtggatagc ggtttgactc acggggattt ccaagtctcc acccattga 780
cgtcaatggg agtttgtttt ggcacaaaaa tcaacgggac tttccaaaat gtcgtaacaa 840
ctccgcccc ttgacgcaaa tggcggttag gcgtgtacgg tgggaggtct atataagcag 900
agctcgttta gtgaaccgtc agatcgctg gagacgccat ccacgtgtt ttgacctcca 960
tagaagacac cgggaccgat ccagcctccg cgccgggaa cggtgcatg gaacgcggat 1020
tcccgtgcc aagagtgcg taagtaccgc ctatagactc tataggcaca cccctttggc 1080
tcttatgcat gctatactgt ttttggcttg ggcctatac acccccgctt ccttatgcta 1140
taggtgatgg tatagcttag cctataggtg tgggttattg accattattg accactcccc 1200
tattggtgac gatactttcc attactaatc cataacatgg ctctttgcca caactatctc 1260
tattggttat atgccaatac tctgtccttc agagactgac acggactctg tatttttaca 1320
ggatggggtc ccatttatta tttaaaaatt cacatataca acaacgcgt ccccggtgcc 1380
cgagttttt attaaacata gcgtgggac tccacgcgaa tctcggttac gtgttccgga 1440
catgggctct tctccggtag cggcgagct tccacatccg agccctggtc ccatgcctcc 1500
agcggctcat ggtcgtcgg cagctccttg ctctaacag tggaggccag acttaggcac 1560
agcacaatgc ccaccaccac cagtgtgccg cacaaggccg tggcggtagg gtatgtgtct 1620
gaaaatgagc gtggagattg ggctcgcacg gctgacgcag atggaagact taaggcagcg 1680
gcagaagaag atgcaggcag ctgagttggt gtattctgat aagagtcaga ggtaaactcc 1740
gttgcggtgc tgttaacggg ggaggcagc gtagtctgag cagtactcgt tgcgtccgcg 1800
cgcgccacca gacataatag ctgacagact aacagactgt tcttttccat ggtcttttc 1860
cgatcctgag aacttcaggg tgagtttggg gacccttgat tgttctttct ttttcgctat 1920
tgtaaaattc atgttatatg gagggggcaa agttttcagg gtgttgttta gaatgggaag 1980
atgtcccttg tatcaccatg gacctcatg ataattttgt ttctttcact tctactctg 2040
ttgacaacca ttgtctcttc ttattttctt ttcatttctt gtaacttttt cgttaaactt 2100
tagcttgcac ttgtaacgaa tttttaaatt cacttttggt tatttgcag attgtaagta 2160
ctttctctaa tcactttttt ttcaaggcaa tcagggtata ttatattgta cttcagcaca 2220
gttttagaga acaattgtta taattaatg ataaggtaga atatttctgc atataaatc 2280
tggctggcgt ggaaatattc ttattggtag aaacaactac atcctggtca tcatcctgcc 2340
tttctcttta tggttacaat gatatacact gtttgagatg aggtataaat actctgagtc 2400
caaaccgggc ccctctgcta accatgttca tgccttcttc ttttctctac agctcctggg 2460
caacgtgctg gttattgtgc tgtctcatca ttttgcaaaa gaattgtaat acgactcact 2520
atagggcgaa ttgtcacctg cgtcgacatg gcggatgtgt gacatacacg acgcaaaaag 2580
attttgttcc agctcctgcc acctccgcta cgcgagagat taaccaccca cgatggccgc 2640
caaagtgcac gttgatattg agcgtgacag cccattcatc aagtctttgc agaaggcatt 2700
tccgtcgttc gaggtggagt cattgcaggt cacaccaaat gacctgcaa atgccagagc 2760
attttcgcac ctggctacca aattgatcga gcaggagact gacaaagaca cactcatctt 2820
ggatatcggc agtgccctt ccaggagaat gatgtctacg cacaaatacc actgcgtatg 2880
ccctatgcgc agcgcagaag accccgaaag gctcgatagc tacgcaaga aactggcagc 2940
ggcctccggg aaggtgctgg atagagagat cgcaggaaaa atcaccgacc tgcagaccgt 3000
catggctacg ccagacgctg aatctcctac cttttgcctg catacagacg tcacgtgtcg 3060
tacggcagcc gaagtggccg tataccagga cgtgtatgct gtacatgcac caacatcgct 3120
gtaccatcag gcgatgaaag gtgtcagaac ggcgtattgg attgggtttg acaccacccc 3180
gtttatgttt gacgcgctag caggcgcgta tccaacctac gccacaaact gggccgacga 3240

```


gcaggtgtta	caggccagga	acataggact	gtgtgcagca	tccttgactg	agggaaagact	3300
cggaacactg	tccattctcc	gcaagaagca	attgaaacct	tcgcacacag	tcatgttctc	3360
ggtaggatct	acattgtaca	ctgagagcag	aaagctactg	aggagctggc	acttaccctc	3420
cgtattccac	ctgaaaggtg	aacaatcctt	tacctgtagg	tcgcatacca	tcgtatcatg	3480
tgaaggggtac	gtagttaaga	aaatcactat	gtgccccggc	ctgtacggtg	aaacggtagg	3540
gtacgccgtg	acgtatcacg	cggaggggatt	cctagtgtgc	aagaccacag	acactgtcaa	3600
aggagaaaga	gtctcattcc	ctgtatgcac	ctacgtcccc	tcaaccatct	gtgatcaaat	3660
gactggcata	ctagcgaccg	acgtcacacc	ggaggacgca	cagaagttgt	tagtgggatt	3720
gaatcagaggy	atagtgtgga	acggaagaac	acagcgaaac	actaacacga	tgaagaacta	3780
tctgcttccg	attgtggccg	tcgcatttag	caagtgggcy	agggaatata	aggcagacct	3840
tgatgatgaa	aaacctctgg	gtgtccgaga	gaggtcactt	acttgctgct	gcttggtggc	3900
atttaaaacg	aggaaatgac	acaccatgta	caagaaacca	gacaccaga	caatagttaa	3960
ggtgccttca	gagtttaact	cgttcgtcat	cccagaccta	tggtctacag	gcctcgcaat	4020
cccagtcaga	tcacgcatta	agatgctttt	ggccaagaag	accaagcgag	agttaatacc	4080
tgttctcgac	cgtcgtcag	ccagggatgc	tgaacaagag	gagaaggaga	ggttggaggc	4140
cgagctgact	agagaagcct	taccacccct	cgtcccatc	gcgccggcgy	agacgggagt	4200
cgtcgacgtc	gacgttgaag	aactagagta	tcacgcaggt	gcaggggtcg	tggaaacacc	4260
tcgcagcgcy	ttgaaagtca	ccgcacagcc	gaacgacgta	ctactaggaa	attacgtagt	4320
tctgtccccg	gcagccgtgc	tcaagagctc	caagttggcc	cccgtgcacc	ctctagcaga	4380
gcaggtgaaa	ataataacac	ataacgggag	ggccggcggt	taccaggtcg	acggatatga	4440
cggcagggtc	ctactaccat	gtggatcgcc	cattccggtc	cctgagtttc	aagctttgag	4500
cgagagcgcc	actatggtgt	acaacgaaag	ggagttcgtc	aacaggaaac	tataccatat	4560
tgccgttcac	ggaccgtcgc	tgaacaccga	cgaggagaac	tacgagaaag	tcagagctga	4620
aagaactgac	gccgagtacg	tgttcgacgt	agataaaaaa	tgctgcgtca	agagagagga	4680
agcgtcggtg	ttggtgttgg	tgggagagct	aaccaacccc	ccgttccatg	aattcgcccta	4740
cgaaaggctg	aagatcaggc	gctcggcacc	atataagact	acagtagtag	gagtccttgg	4800
ggttccggga	tcaggcaagt	ctgctattat	taagagcctc	gtgaccaaac	acgatctggt	4860
caccagcgcc	aagaaggaga	actgccagga	aatagttaac	gacgtgaaga	agcaccgcyg	4920
gaaggggaca	agtagggaaa	acagtgactc	catcctgcta	aacgggtgtc	gtcgtgccgt	4980
ggacatccta	tatgtggacg	aggctttcgc	ttgccattcc	ggtactctgc	tggccctaata	5040
tgctcttgtt	aaacctcgga	gcaaagtggg	gttatgcgga	gaccccaagc	aatgcygatt	5100
cttcaatatg	atgcagctta	agggtgaactt	caaccacaac	atctgcactg	aagtatgtca	5160
taaaagtata	tccagacgtt	gcacgcgtcc	agtcacggcc	atcgtgtcta	cgttgacta	5220
cggaggcaag	atgcgcacga	ccaacccgtg	caacaaaccc	ataatcatag	acaccacagg	5280
acagaccaag	cccaagccag	gagacatcgt	gttaacatgc	ttccgagggt	gggcaaaagca	5340
gctgcagttg	gactaccgtg	gacacgaagt	catgacagca	gcagcatctc	agggccctac	5400
ccgcaaaagg	gtatacgccg	taaggcagaa	ggtgaatgaa	aatcccttgt	atgccctgc	5460
gtcggagcac	gtgaatgtac	tgctgacgcy	cactgaggat	aggctggtgt	ggaaaacgct	5520
ggccggcgat	ccctggattg	aggtcctatc	aaacattcca	cagggttaact	ttacggccac	5580
attggaagaa	tggcaagaag	aacacgacaa	aataatgaag	gtgattgaag	gaccggctgc	5640
gcctgtggac	gcgttccaga	acaaaagcga	cgtgtgttgg	gcgaaaagcc	tgggtccctgt	5700
cctggacact	gccggaatca	gattgacagc	agaggagtgg	agcaccataa	ttacagcatt	5760
taaggaggac	agagcttact	ctccagtggg	ggccttgaat	gaaatttgca	ccaagtacta	5820
tggagtgtac	ctggacagtg	gcctgttttc	tgccccgaag	gtgtccctgt	attacgagaa	5880
caaccactgg	gataacagac	ctggttgaag	gatgtatgga	ttcaatgccg	caacagctgc	5940
caggctggaa	gctagacata	ccttctctgaa	ggggcagtg	catacgggca	agcaggcagt	6000
tatcgagaa	agaaaatcc	aaccgctttc	tgtgctggac	aatgtaattc	ctatcaaccg	6060
caggctgccg	cacgccttgg	tggctgagta	caagacgggt	aaaggcagta	gggttgagtg	6120
gctggtcaat	aaagtaagag	ggtaccacgt	cctgctgggt	agttagtaca	acctggcttt	6180
gcctcgacgc	agggtcactt	ggttgtcacc	gctgaatgtc	acaggcgccg	ataggtgcta	6240
cgacctaaat	ttaggactgc	cggctgacgc	cggcaggttc	gacttggctc	ttgtgaacat	6300
tcacacggaa	ttcagaatcc	accactacca	gcagtgtgtc	gaccacgcca	tgaagctgca	6360
gatgcttggg	ggagatgcgc	tacgactgct	aaaacccggc	ggcatcttga	tgagagctta	6420
cggaatcgcc	gataaaatca	gcgaagccgt	tgttctctcc	ttaagcagaa	agttctcgtc	6480
tgcaagagtg	ttgcgcccgg	attgtgtcac	cagcaatata	gaagtgttct	tgctgttctc	6540
caactttgac	aacggaaaga	gacctctac	gctacaccag	atgaatacca	agctgagtgc	6600
cgtgtatgcc	ggagaagcca	tgacacagcc	cgggtgtgca	ccatcctaca	gagttaagag	6660

agcagacata gccacgtgca cagaagcggc tgtgggttaac gcagctaabg cccgtggaac 6720
 tgtaggggat ggcgtatgca gggccgtggc gaagaaatgg ccgtcagcct ttaagggagc 6780
 agcaacacca gtgggcacaa ttaaaacagt catgtgcggc tctaccccg tcatccacgc 6840
 tgtagcgccct aatttctctg ccacgactga agcgggaagg gaccgcgaat tggccgctgt 6900
 ctaccgggca gtggccggccg aagtaaacag actgtcactg agcagcgtag ccatcccgt 6960
 gctgtccaca ggagtgttca gcggcggaaag agataggctg cagcaatccc tcaaccatct 7020
 attcacagca atggagccca cggacgctga cgtgaccatc tactgcagag acaaaagtgt 7080
 ggagaagaaa atccagggaag ccattgacat gaggacggct gtggagtgc tcaatgatga 7140
 cgtggagctg accacagact tggtagaggt gcacccggac agcagcctgg tgggtcgtaa 7200
 gggctacagt accactgacg ggtcgtctga ctcgtacttt gaaggtagca aattcaacca 7260
 ggctgtatt gatattggcag agatactgac gttgtggccc agactgcaag aggcaaacga 7320
 acagatatgc ctatacgcg tggcggaac aatggacaac atcagatcca aatgtccggt 7380
 gaacgattcc gattcatcaa cacctcccag gacagtgcct tgcctgtgcc gctacgcaat 7440
 gacagcagaa cggatgcgcc gccttaggtc acaccaagtt aaaagcatgg tggtttgcct 7500
 atcttttccc ctcccgaat accatgtaga tgggtgagc aggttaaagt gcgagaaggt 7560
 tctcctgttc gaccgcgagc taccttcagt ggttagtccg cggaagtatg ccgcatctac 7620
 gacggaccac tcagatcggt cgttacgagg gtttgacttg gactggacca ccgactcgtc 7680
 ttccactgcc agcgatacca tgtcgtctacc cagtttgagc tctgtgtaca tgcactcgat 7740
 ctacgagcca atggctccca tagtagtgac ggctgacgta caccctgaac ccgcaggcat 7800
 cgcggacctg gcggcagatg tgcacctga acccgagac catgtggacc tcgagaacct 7860
 gattcctcca ccgcgcccga agagagctgc ataccttgcc tcccgcgagg cgagcgacc 7920
 ggtgcggcg ccgagaaagc cgacgcctgc cccaaggact gcgtttagga acaagctgcc 7980
 tttgacgttc ggcgactttg acgagcacga ggtcgatgcg ttggcctccg ggattacttt 8040
 cggagacttc gacgacgtcc tgcgactagg ccgcgcgggt gcataatatt tctcctcgga 8100
 cactggcagc ggacatttac aacaaaaatc cgttaggcag cacaatctcc agtgcgcaca 8160
 actggatgcg tcccaggag agaaaatgta cccgcaaaa ttggatactg agagggagaa 8220
 gctgttgctg ctgaaaatgc agatgcaccc atcggaggct aataagagtc gataccagtc 8280
 tcgcaaatg gagaacatga aagccacggt ggtggacagg ctcacatcgg gggccagatt 8340
 gtacacggga gcggacgtag gccgcatacc aacatacgcg gttcggtagc cccgccccgt 8400
 gtactcccc accgtgatcg aaagattctc aagccccgat gtagcaatcg cagcgtgcaa 8460
 cgaatacccta tccagaaatt acccaacagt ggcgtcgtac cagataacag atgaatacga 8520
 cgcatacttg gacatggttg acgggtcgga tagttgcttg gacagagcga cattctgccc 8580
 ggcgaagctc cgtgtctacc cgaaacatca tgcgtaccac cagccgactg tacgcagtgc 8640
 cgtcccgtca ccctttcaga acacactaca gaacgtgcta gcggccgcca ccaagagaaa 8700
 ctgcaacgct acgcaaatgc gagaactacc caccatggac tggcagtggt tcaacgtgga 8760
 gtgcttcaag cgtctgcct gctccggaga atattggga gaatatgcta aacaacctat 8820
 ccggataacc actgagaaca tcaactaccta tgtgacaaa ttgaaaggcc cgaagactgc 8880
 tgccttgctc gctaagaccc acaacttggt tccgctgcag gaggttccca tggacagatt 8940
 cacggtcgac atgaaacgag atgtcaaagt cactccaggg acgaaacaca cagaggaaa 9000
 acccaagtc caggtaattc aagcagcgga gccattggcg accgcttacc tgtgcggcat 9060
 ccacagggaa ttagtaagga gactaaatgc tgtgttacgc cctaacgtgc acacattggt 9120
 tgatatgtcg gccgaagact ttgacgcat catgcctct cacttcacc caggagaccc 9180
 ggttctagag acggacattg catcattcga caaaagccag gacgactcct tggctcttac 9240
 aggtttaatg atcctcgaag atctagggtt ggatcagtag ctgctggact tgatcgaggc 9300
 agcctttggg gaaatatcca gctgtcacct accaactggc acgcgcttca agttcggagc 9360
 tatgatgaaa tcgggcatgt ttctgacttt gtttattaac actgttttga acatcaccat 9420
 agcaagcagg gtactggagc agagactcac tgactccgc tgtgcggcct tcatcgcgga 9480
 cgacaacatc gttcacggag tgatctccga caagctgatg gcggagaggt gcgcgtcgtg 9540
 ggtcaacatg gaggtgaaga tcattgacgc tgtcatgggc gaaaaacccc catatttttg 9600
 tgggggatc atagtttttg acagcgtcac acagaccgcc tgccgtgttt cagacccact 9660
 taagcgcctg ttcaagtttg gtaagccgct aacagctgaa gacaagcagg acgaagacag 9720
 gcgacgagca ctgagtgcag aggttagcaa gtggttccgg acaggcttgg gggccgaact 9780
 ggaggtggca ctaacatcta ggtatagggt agagggctgc aaaagtatcc tcatagccat 9840
 ggccaccttg gcgagggaca ttaaggcgtt taagaaattg agaggacctg ttatacacct 9900
 ctacggcggt cctagattgg tgcgttaata cacagaattc tgattggatc atagcgact 9960
 attataggat ccgcgcgcgc gaattcggca cgagtaacaa tggagttgct aatcctcaaa 10020
 gcaaatgcaa ttaccacaat cctcactgca gtcacatttt gttttgcttc tgggtcaaac 10080

10/16

atcactgaag	aattttatca	atcaacatgc	agtgcagtta	gcaaaggcta	tcttagtgct	10140
ctgagaactg	gttggtatac	cagtgttata	actatagaat	taagtaatat	caaggaaaat	10200
aagtgtaatg	gaacagatgc	taaggtaaaa	ttgataaaaac	aagaattaga	taaatataaa	10260
aatgctgtaa	cagaattgca	gttgctcatg	caaagcacac	cagcagcaaa	caatcgagcc	10320
agaagagaac	taccaagggtt	tatgaattat	acactcaaca	atgccaaaaa	aaccaatgta	10380
acattaagca	agaaaaggaa	aagaagattt	cttggttttt	tgtaggtgt	tggtactgca	10440
atcgccagtg	gcgttgctgt	atctaaggtc	ctgcacctag	aaggggaagt	gaacaagatc	10500
aaaagtgtc	tactatccac	aaacaaggct	gtagtcagct	tatcaaatgg	agttagtgtc	10560
ttaaccagca	aagtgttaga	cctcaaaaac	tatatagata	aacaattgtt	acctattgtg	10620
aacaagcaaa	gctgcagcat	atcaaatata	gaaactgtga	tagagttcca	acaaaagaac	10680
aacagactac	tagagattac	caggggaattt	agtgttaatg	caggtgtaac	tacacctgta	10740
agcacttaca	tgtaactaa	tagtgaatta	ttgtcattaa	tcaatgatata	gcctataaca	10800
aatgatcaga	aaaagttaat	gtccaacaat	gttcaaatag	ttagacagca	aagttactct	10860
atcatgtcca	taataaaaaga	ggaagtctta	gcatatgtag	tacaattacc	actatatggt	10920
gttatagata	cacctgtgtg	gaaactacac	acatccccctc	tatgtacaac	caacacaaaa	10980
gaaggggtcca	acatctgttt	aacaagaact	gacagaggat	ggtactgtga	caatgcagga	11040
tcagtatctt	tcttcccaca	agctgaaaca	tgtaaaagttc	aatcaaatcg	agtattttgt	11100
gacacaaatga	acagtttaac	attaccaagt	gaaataaatc	tctgcaatgt	tgacatatct	11160
aaccccaat	atgattgtaa	aattatgact	tcaaaaacag	atgtaagcag	ctccgttctc	11220
acatctctag	gagccattgt	gtcatgctat	ggcaaaacta	aatgtacagc	atccaataaa	11280
aatcgtggaa	tcataaagac	attttctaac	gggtgcgatt	atgtatcaaa	taaaaggatg	11340
gacactgtgt	ctgtaggtaa	cacattatat	tatgtaaaata	agcaagaagg	taaaagtctc	11400
tatgtaaaag	gtgaaccaat	aataaatttc	tatgacccat	tagtattccc	ctctgatgaa	11460
tttgatgcat	caatatctca	agtcaacgag	aagattaacc	agagcctagc	atttattcgt	11520
aaatccgatg	aattattaca	taatgtaaat	gctggtaaat	ccaccacaaa	tatcatgact	11580
tgataatgag	gatccagatc	ccgggtaatt	aattgaatta	catccctacg	caaacgtttt	11640
acggccgccc	gtggcgccc	cgcccgccg	cccgtccttg	gccgttgtag	gccactccgg	11700
tggtccccgt	cgtccccgac	ttccaggccc	agcagatgca	gcaactcatc	agcgccgtaa	11760
atgcgctgac	aatgagacag	aacgcaattg	ctcctgctag	gcctcccaaa	ccaaagaaga	11820
agaagacaac	caaaccaaa	ccgaaaacgc	agcccaagaa	gatcaacgga	aaaacgcagc	11880
agcaaaagaa	gaaagacaag	caagccgaca	agaagaagaa	gaaaccgga	aaaagagaaa	11940
gaatgtgcat	gaagattgaa	aatgactgta	tcttcgtatg	cggctagcca	cagtaacgta	12000
gtgtttccag	acatgtcggg	caccgcacta	tcatgggtgc	agaaaatctc	gggtgggtctg	12060
ggggccctcg	caatcggcgc	tatectgggtg	ctggttgggtg	tcacttgcat	tgggctccgc	12120
agataagtta	gggtaggcaa	tggcattgat	atagcaagaa	aattgaaaac	agaaaaagtt	12180
agggtaaaga	atggcatata	accataactg	tataacttgt	aacaaagcgc	aacaagacct	12240
gcgcaattgg	ccccgtggtc	cgctcacgg	aaactcgggg	caactcatat	tgacacatta	12300
attggcaata	attggaagct	tacataagct	taattcgacg	aataattgga	tttttatattt	12360
attttgcaat	tggtttttta	tatttccaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	12420
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	gcgggtcggc	atggcatctc	12480
cacctcctcg	cggtccgacc	tgggcatccg	aaggaggacg	cacgtccact	cggatggcta	12540
agggagagat	ccagatctgc	tgtgccttct	agttgccagc	catctgttgt	ttgcccctcc	12600
cccggtgcctt	ccttgaccct	ggaaggtgcc	actcccactg	tcctttccta	ataaaatgag	12660
gaaattgcat	cgcattgtct	gagtaggtgt	cattctattc	tggggggtgg	ggtggggcag	12720
gacagcaagg	gggaggattg	ggaagacaat	agcaggcatg	ctggggatgc	ggtgggctct	12780
atgggtaccc	aggtgctgaa	gaattgaccc	ggttcctcct	gggccagaaa	gaagcaggca	12840
catccccttc	tctgtgacac	accctgtcca	cgccccgtgt	tcttagttcc	agccccactc	12900
atagacact	catagctcag	gagggctccg	ccttcaatcc	caccogctaa	agtacttggg	12960
gcggctctctc	cctcccctcat	cagcccacca	aaccaaacct	agcctccaag	agtgggaaga	13020
aattaaagca	agataggcta	ttaagtgcag	agggagagaa	aatgcctcca	acatgtgagg	13080
aagtaatgag	agaaatcata	gaatttcttc	cgcttcctcg	ctcactgact	cgtgcgctc	13140
ggtcgttcgg	ctgcggcgag	cggtatcagc	tcactcaaag	gcggtaatac	ggttatccac	13200
agaatcaggg	gataacgcag	gaaagaacat	gtgagcaaaa	ggccagcaaa	aggccaggaa	13260
ccgtaaaaag	gccgcgttgc	tggcggtttt	ccataggctc	cgccccctg	acgagcatca	13320
caaaaatcga	cgctcaagtc	agaggtggcg	aaacccgaca	ggactataaa	gataccaggc	13380
gtttccccct	ggaagctccc	tcgtgcgctc	tcctgttccg	accctgccgc	ttaccggata	13440
cctgtccgcc	tttctccctt	cgggaagcgt	ggcgctttct	catagctcac	gctgtaggta	13500


A93D

11/16

tctcagttcg	gtgtaggtcg	ttcgcctcaa	gctgggctgt	gtgcacgaac	cccccgttca	13560
gccccaccgc	tgcgccttat	ccggttaacta	tcgtcttgag	tccaacccgg	taagacacga	13620
cttatcgcca	ctggcagcag	ccactggtaa	caggattagc	agagcgaggt	atgtaggcgg	13680
tgtacagag	ttcttgaagt	ggtggcctaa	ctacggctac	actagaagaa	cagtatttgg	13740
tatctgcgt	ctgctgaagc	cagttacctt	cggaaaaaga	gttggtagct	cttgatccgg	13800
caaacaacc	accgctggta	gcggtggttt	ttttgtttgc	aagcagcaga	ttacgcgcag	13860
aaaaaaagga	tctcaagaag	atcctttgat	cttttctacg	gggtctgacg	ctcagtggaa	13920
cgaaaactca	cgtaaggga	ttttggctcat	gagattatca	aaaaggatct	tcacctagat	13980
ccttttaaat	taaaaatgaa	gttttaaatc	aatctaaagt	atatatgagt	aaacttggtc	14040
tgacagttac	caatgcttaa	tcagtgaagc	acctatctca	gcgatctgtc	tatttcgttc	14100
atccatagtt	gcctgactcg	gggggggggg	gcgctgaggt	ctgcctcgtg	aagaaggtgt	14160
tgtgactca	taccaggcct	gaatcgcccc	atcatccagc	cagaaagtga	gggagccacg	14220
gttgatgaga	gctttgttgt	aggtggacca	gttggtgatt	ttgaactttt	gctttgccac	14280
ggaacggtct	gcgttgctcg	gaagatgcgt	gatctgatcc	ttcaactcag	caaaagttcg	14340
atttattcaa	caaagccgcc	gtcccgtcaa	gtcagcgtaa	tgctctgcca	gtgttacaac	14400
caattaacca	attgtgatta	gaaaaactca	tcgagcatca	aatgaaactg	caatttatcc	14460
atatcaggat	tatcaatacc	atatttttga	aaaagccggt	tctgtaatga	aggagaaaac	14520
tcaccgaggc	agttccatag	gatggcaaga	tcctggtatc	ggtctcgat	tccgactcgt	14580
ccaacatcaa	tacaacctat	taatttcccc	tcgtcaaaaa	taagggtatc	aagtgagaaa	14640
tcaccatgag	tgacgactga	atccgggtgag	aatggcaaaa	gcttatgcat	ttctttccag	14700
acttgttcaa	caggccagcc	attacgctcg	tcatcaaaaat	cactcgcatc	aaccaaaccg	14760
ttattcatte	gtgattgcgc	ctgagcgaga	cgaaatacgc	gatcgctgtt	aaaaggacaa	14820
ttacaaacag	gaatcgaatg	caaccggcgc	aggaacactg	ccagcgcatc	aacaatattt	14880
tcacctgaat	caggatatcc	ttctaatacc	tggaaatgctg	ttttcccggg	gatcgcagtg	14940
gtgagtaacc	atgcatcatc	aggagtacgg	ataaaatgct	tgatggctcg	aagaggcata	15000
aattccgtca	gccagtttag	tctgaccatc	tcactctgtaa	catcattggc	aacgctacct	15060
ttgccatggt	tcagaaacaa	ctctggcgca	tcgggcttcc	catacaatcg	atagattgtc	15120
gcacctgatt	gcccgcacatt	atcgcgagcc	catttatacc	catataaatc	agcatccatg	15180
ttggaattta	atcgcggcct	cgagcaagac	gtttcccgtt	gaatatggct	cataacgttc	15240
cttgtattac	tgtttatgta	agcagacagt	tttattgttc	atgatgatat	atttttatct	15300
tgtgcaatgt	aacatcagag	attttgagac	acaacgtggc	tttccccccc	ccccattat	15360
tgaagcattt	atcagggtta	ttgtctcatg	agcggataca	tatttgaatg	tatttagaaa	15420
aataaacaaa	taggggttcc	gcgcacattt	ccccgaaaag	tgccacctga	cgtctaagaa	15480
accattatta	tcatgacatt	aacctataaa	aataggcgta	tcacgaggcc	ctttcgtc	15538

12/16

Figure 4. Anti-RSV F titres in sera from mice taken 4 weeks after priming and 2 weeks after boosting



13/16

Figure 5 Ribozyme linker for pMP42

5' 3'
CTAGCGGGTCGGCATCTCCACCTCCTCGCGGTCCGACCTGGGCATCCGAAGGAGGACGACGTCCTCCACTCGGATGGCTAAGGGAGA
GCCCAGCCGTACCGTAGAGGTTGAGGAGCGCCAGGCTGGACCCGTTAGGCTTCTCTGCGTGCAGGTGAGCCCTACCGATTCCCTCTCTAG

Figure 6ASFV Eco RV-Spe I fragment ligated to ribozyme

	atcggcagtg	cgccttccag	gagaatgatg	tctacgcaca	aataccactg	cgtatgccct	60
	atgcgcagcg	cagaagaccc	cgaaaggctc	gatagctacg	caaagaaact	ggcagcggcc	120
	tccgggaagg	tgctggatag	agagatcgca	ggaaaaatca	ccgacctgca	gaccgtcatg	180
5	gctacgccag	acgctgaatc	tcttaccttt	tgccctgcata	cagacgtcac	gtgtcgtacg	240
	gcagccgaag	tgcccgata	ccaggacgtg	tatgtctgtac	atgcaccaac	atcgtgttac	300
	catcaggcga	tgaaaggtgt	cagaacggcg	tattggattg	ggtttgacac	caccccgttt	360
	atgtttgacg	cgctagcagg	cgcgtatcca	acctacgcca	caaaactggc	cgacgagcag	420
	gtgttacagg	ccaggaacat	aggactgtgt	gcagcatcct	tgactgaggg	aagactcggc	480
10	aaactgtcca	ttctccgcaa	gaagcaattg	aaaccttgcg	acacagtcac	gttctcggta	540
	ggatctacat	tgtacactga	gagcagaaag	ctactgagga	gctggcactt	accctccgta	600
	ttccacctga	aaggtaaaaca	atcctttacc	tgtaggtgcg	ataccatcgt	atcatgtgaa	660
	gggtacgtag	ttaagaaaat	cactatgtgc	cccggcctgt	acggtaaaac	ggtagggtag	720
	gccgtgacgt	atcacgcgga	gggattccta	gtgtgcgaaga	ccacagacac	tgtcaaaagg	780
15	gaaagagtct	cattccctgt	atgcacctac	gtccctctca	ccatctgtga	tcaaagtact	840
	ggcatactag	cgaccgacgt	cacaccggag	gacgcacaga	agttgttagt	gggattgaat	900
	cagaggatag	gcattgaacg	aagaacacag	cgaaacacta	acacgatgaa	gaactatctg	960
	cttccgattg	tgcccgctgc	atttagcaag	tgggcgaggg	aatacaaggg	agaccttgat	1020
	gatgaaaaac	ctctgggtgt	ccgagagagg	tcacttactt	gctgctgctt	gtgggcattt	1080
20	aaaacgagga	agatgcacac	catgtacaag	aaaccagaca	cccagacaat	agtgaagggt	1140
	ctttcagagt	ttaactcggt	cgatcatccg	agcctatggt	ctacaggcct	cgcaatccca	1200
	gtcagatcac	gcattaaagt	gcttttgccc	aagaagacca	agcagagagt	aatacctgtt	1260
	ctcagcgcgt	cgctagccag	ggatgctgaa	caagaggaga	aggagaggtt	ggaggccgag	1320
	ctgactagag	aagccttacc	accctcgtc	cccacgcgc	cggcggagac	gggagtcgtc	1380
25	gacgtcgacg	ttgaagaact	agagtatcac	gcagggtcag	gggtcgtgga	aacacctcgc	1440
	agcgcggtga	aagtcaccgc	acagccgaac	gacgtactac	taggaaatta	cgtagtctctg	1500
	tcccgcgaga	ccgtgctcaa	gagctccaag	ttggccccc	tgcacctct	agcagagcag	1560
	gtgaaaaata	taaacacata	cgggagggcc	ggcggttacc	aggtcgacgg	atatgacggc	1620
	agggctctac	taccatgtgg	atcggccatt	ccggtccctg	agtttcaagc	tttgagcgag	1680
30	agcgccacta	tggtgtacaa	cgaaagggag	ttcgtcaaca	ggaaactata	ccatattgcc	1740
	gttcacggac	cgctcgtgaa	caccgacgag	gagaactacg	agaaagtcag	agctgaaaga	1800
	actgacgccc	cgactgtggt	cyacgtagat	aaaaaatgct	gcgtcaagag	agagggaagc	1860
	tccgggtttg	tggtgtggg	agagctaacc	aacccccgt	tccatgaatt	cgctacgaa	1920
	gggtggaaga	tcaggccgct	ggcaccatat	aagactacag	tagtaggagt	ctttgggggt	1980
35	ccgggatcag	gcaagtctgc	tattattaag	agcctcgtga	ccaaacacga	tctggtcacc	2040
	agcggcaaga	aggagaactg	ccaggaaata	gttaacgacg	tgaagaagca	ccgcgggaag	2100
	gggacaagta	gggaaaacag	tgactccatc	ctgctaaacg	ggtgtcgtcg	tgccgtggac	2160
	atcctatatg	tggacgaggg	tttcgcttgc	cattccggta	ctctgctggc	cctaattgct	2220
	cttgttaaac	ctcggagcaa	agtgggtgta	tgcggagacc	ccaagcaatg	cggattcttc	2280
40	aatatgatgc	agcttaaggt	gaacttcaac	cacaacatct	gcactgaagt	atgtcataaa	2340
	agtatatcca	gacgttgac	gcgtccagtc	acggccatcg	tgtctacgtt	gcactacgga	2400
	ggcaagatgc	gcacgaccaa	cccgtgcaac	aaaccataa	tcatagacac	cacaggacag	2460
	accaagccca	agccagggaga	catcgtgtta	acatgcttcc	gaggtggggc	aaagcagctg	2520
	cagttggact	accgtggaga	cgagtcagtg	acagcagcag	catctcaggg	cctcaccggc	2580
45	aaaggggtat	acgcccgaag	gcagaaggtg	aatgaaaatc	ccttgatgac	ccctgcgtcg	2640
	gagcacgtga	atgtactgct	gacgcgcact	gaggataggg	tggtgtggaa	aacgctggcc	2700
	ggcgatccct	ggattaaggt	cctatcaaac	attccacagg	gtaactttac	ggccacattg	2760
	gaagaatggc	aagaagaaca	cgacaaaata	atgaagggtg	ttgaaggacc	ggctgcgctt	2820
	gtggacgcgt	tccagaacaa	agcgaacgtg	tggtggcgga	aaagcctggg	gcctgtcctg	2880
50	gacactgcgt	gaatcagatt	gacagcagag	gagtgaggca	ccataattac	agcatttaag	2940
	gagggacagag	cttactctcc	agtgggtggc	ttgaatgaaa	tttgcaccaa	gtactatgga	3000
	gttgacctgg	acagtgccct	gttttctgcc	ccgaagggtg	ccctgtatta	cgagaacaa	3060
	cactgggata	acagacctgg	tggaaaggatg	tatggattca	atgccgcaac	agctgccagg	3120
	ctggaagcta	gacatacctt	cctgaagggg	cagtggcata	cgggcaagca	ggcagttatc	3180
55	gcagaagaa	aaatccaacc	gctttctgtg	ctggacaatg	taattcctat	caaccgcagg	3240
	ctgccgcacg	ccctgggtggc	tgagtacaag	acgggttaag	gcagtagggt	tgagtggctg	3300
	gtcaataaag	taagagggtg	ccacgtcctg	ctgggtgagt	agtacaacct	ggcttgcctt	3360
	cgacgcaggg	tcacttgggt	gtcaccgctg	aatgtcacag	gcgccgatag	gtgctacgac	3420

Ac.66

	ctaagtttag	gactgccggc	tgacgccggc	aggttcgact	tggctcttgt	gaacattcac	3480
	acgyaattca	gaatccacca	ctaccagcag	tgtgtcgacc	acgccatgaa	gctgcagatg	3540
	cttgggggag	atgcgctacg	actgctaaaa	cccggcgga	tcttgatgag	agcttacgga	3600
	tacgccgata	aaatcagcga	agcggttgtt	tcctccttaa	gcagaaagt	ctcgtctgca	3660
5	agagtgttgc	gcccggattg	tgccaccagc	aatacagaag	tgttcttgc	gttctccaac	3720
	tttgacaacg	gaaagagacc	ctctacgcta	caccagatga	ataccaagct	gagtgcctg	3780
	tatgccggag	aagccatgca	cacggccggg	tgtgcacat	cctacagagt	taagagagca	3840
	gacatagcca	cgtgcacaga	agcggctgtg	gttaacgcag	ctaacgccc	tggaaactgta	3900
	ggggatggcg	tatgcagggc	cgtggcggaag	aaatggccgt	cagccttta	gggagcagca	3960
10	acaccagtgg	gcacaattaa	aacagtcagt	tgccggtcgt	accccgctcat	ccacgctgta	4020
	gcgcctaatt	tctctgccac	gactgaagcg	gaaggggacc	gcgaattggc	cgctgtctac	4080
	cgggcagtgg	ccgcgaag	taactgagca	gcgtagccat	cccgtgctg	cccgctgctg	4140
	tccacaggag	tgttcaagcg	cggaagagat	aggctgcagc	aatccctcaa	ccatctattc	4200
	acagcaatgg	acgccacgga	cgctgacgtg	accatctact	gcagagacaa	aagttgggag	4260
15	aagaaaatcc	aggaagccat	tgacatgagg	acggctgtgg	agttgctcaa	tgatgacgtg	4320
	gagctgacca	cagacttggg	gagagtgcac	ccggacagca	gcttgggtgg	tcgtaagggc	4380
	tacagtacca	ctgacgggtc	gctgtactcg	tactttgaag	gtacgaaatt	caaccaggct	4440
	gctattgata	tggccagatg	actgacgttg	tggcccgagc	tgcaagagcg	aaacgaacag	4500
	atatgcctat	acgcgctggg	cgaaacaatg	gacaacatca	gatccaaatg	tcgggtgaac	4560
20	gattccgatt	catcaacacc	tcccaggaca	gtgccctgcc	tgtgccgcta	cgcaatgaca	4620
	gcagaacgga	tcgcccgcct	taggtcacac	caagttaaaa	gcattgggtg	ttgctcatct	4680
	tttcccctcc	cgaaatacca	tgtagatggg	gtgcagaagg	taaaagtgcg	gaaggttctc	4740
	ctgttcgacc	cgagcctacc	ttcagtgggt	agtcgcggga	agtatgccgc	atctacgacg	4800
	gaccactcag	atcggctcgt	acgaggggtt	gacttggaat	ggaccaccca	ctcgtcttcc	4860
25	actgccagcg	ataccatgtc	gctacccagt	ttgcagtcgt	gtgacatcga	ctcgatctac	4920
	gagccaatgg	ctcccatagt	agtgcagggc	gacgtacacc	ctgaacccgc	aggcatcgcg	4980
	gacctggcgg	cagatgtgca	cctgaaccc	gcagaccatg	tggacctcga	gaacccgatt	5040
	cctccaccgc	gcccgaagag	agctgcatac	cttgccctcc	gcgcggcgga	gcgaccgggtg	5100
	ccggcgccga	gaaagccgac	gcctgcccc	aggactgcgt	ttaggaacaa	gctgcctttg	5160
30	acgttcggcg	actttgaoga	gcacgaggtc	gatgcgttgg	cctccgggat	tactttcgga	5220
	gacttcgacg	acgtcctcgc	actaggccgc	gcgggtgcac	atattttctc	ctcggacact	5280
	ggcagcggac	atttacaaca	aaaatccgtt	aggcagcaca	atctccagtg	cgcaacaactg	5340
	gatgcgggtc	aggaggagaa	aatgtaccgc	ccaaaattgg	atactgagag	ggagaagctg	5400
	ttgtctgctg	aaatgcagat	gcacccatcg	gaggctaata	agagtgcata	ccagtctcgc	5460
35	aaagtggaga	acatgaaagc	cacggtgggtg	gacaggtcca	catcgggggc	cagattgtac	5520
	acgggagcgg	acgtaggccg	cataccaaca	tacgcgggtc	ggtaccccc	ccccgtgtac	5580
	tcccctaccg	tgatcgaaag	attctcaagc	cccgatgtag	caatcgagc	gtgcaacgaa	5640
	tacctatcca	gaaattaccc	aacagtggcg	tcgtaccaga	taacagatga	atacgacgca	5700
	tacttggaca	tggttgacgg	gtcggatagt	tgcttggaca	gagcgacatt	ctgcccggcg	5760
40	aagctccggg	gctaccggaa	acatcatgcg	taccaccagc	cgactgtacg	cagtgcctgc	5820
	ccgtcaccct	ttcagaacac	actacagaac	gtgctagcgg	ccgccaccaa	gagaaactgc	5880
	aacgtcacgc	aaatgcgaga	actaccacc	atggactcgg	cagtgttcaa	cgtggagtgc	5940
	ttcaagcgct	atgcctgtc	cggagaatat	tgggaagaat	atgctaaaca	acctatccgg	6000
	ataaccactg	agaaccatcac	tacctatgtg	accaaattga	aaggccccga	agctgctgcc	6060
45	ttgttcgcta	agaccacaaa	cttgggtccg	ctgcaggagg	ttcccatgga	cagattcacg	6120
	gtcgacatga	aacgagatgt	caaagtcaat	ccagggacga	aacacacaga	ggaaagaccc	6180
	aaagtccagg	taattcaagc	agcggagcca	ttggcgaccg	cttacctgtg	cggcacccac	6240
	agggaaattg	taaggagact	aaatgctgtg	ttacgcctta	acgtgcacac	attgtttgat	6300
	atgtcggccg	aagactttga	cgcgatcacc	gcctctcact	tcacccagg	agacccgggt	6360
50	ctagagacgg	acattgcacc	attcgacaaa	agccaggacg	actccttggc	tcttacaggt	6420
	ttaatgatcc	tcgaagatct	aggggtggat	cagtacctgc	tggacttgat	cgaggcagcc	6480
	tttggggaaa	tatccagctg	tcacctacca	actggcacgc	gcttcaagtt	cgagctatg	6540
	atgaaatcgg	gcatgtttct	gactttgttt	attaacactg	ttttgaacat	caccatagca	6600
	agcaggggtac	tggagcagag	actcactgac	tcgcctgtg	cggccttcat	cggcgacgac	6660
55	aacatcgttc	acggagtgtg	ctccgacaa	ctgatggcgg	agaggtgcgc	gtcgtgggtc	6720
	aacatggagg	tgaagatcat	tgacgtgtgc	atgggcgaaa	aacccccata	tttttggggg	6780
	ggattcatag	tttttgacag	cgtcacacag	accgcctgcc	gtgtttcaga	cccacttaag	6840
	cgctgttca	agttgggtaa	gcccgaaca	gctgaagaca	agcaggacga	agacaggcga	6900
	cgagcactga	gtgacgaggt	tagcaagtgg	ttccggacag	gcttgggggc	cgaactggag	6960

446c

gtggcactaa catctaggta tgaggtagag ggctgcaaaa gtatcctcat agccatggcc 7020
accttggcga gggacattaa ggcgtttaag aaattgagag gacctgttat acacctctac 7080
ggcggctcta gattggtgcg ttaatacaca gaattctgat tggatcatag cgcactatta 7140
taggatccag atcccggtta attaattgaa ttacatccct acgcaaacgt ttacggccg 7200
5 cgggtggcgc ccgcgcccgc cggcccgtcc ttggccggtg caggccactc cgttggctcc 7260
cgctgtcccc gacttccagg ccagcagat gcagcaactc atcagcgccg taaatgcgct 7320
gacaatgaga cagaacgcaa ttgctcctgc taggcctccc aaaccaaaga agaagaagac 7380
aaccaaacca aagccgaaaa cgcagcccaa gaagatcaac ggaaaaacgc agcagcaaaa 7440
gaagaagac aagcaagccg acaagaagaa gaagaaaccc ggaaaaagag aaagaatgtg 7500
10 catgaagatt gaaaatgact gtatcttcgt atgcggctag ccacagtaac gtagtgtttc 7560
cagacatgtc gggcaccgca ctatcatggg tgcagaaaat ctgggtgggt ctgggggcct 7620
tcgcaatcgg cgctatcctg gtgctgggtg tggtcacttg cattgggttc cgcagataag 7680
ttagggtagg caatggcatt gatatagcaa gaaaattgaa aacagaaaaa gttagggtta 7740
gcaatggcat ataaccataa ctgtataact tgtaacaaag cgcaacaaga cctgcgcaat 7800
15 tggccccgtg gtccgcctca cggaaactcg gggcaactca tattgacaca ttaattggca 7860
ataattggaa gcttacataa gcttaattcg acgaataatt ggatttttat tttattttgc 7920
aattggtttt taatatttcc aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 7980
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa ctagcgggtc ggcattggcat ctccacctcc 8040
20 tcgcggtccg acctgggcat ccgaaggagg acgcacgtcc actcggatgg ctaagggaga 8100

INTERNATIONAL SEARCH REPORT

Inter. .onal Application No

PCT/CA 98/01064

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/86 C12N15/45 C07K14/135 C07K14/115 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 96 40945 A (CONNAUGHT LAB ;LI XIAOMAO (CA); EWASYSHYN MARY'E (CA); SAMBHARA SU) 19 December 1996 cited in the application see the whole document, especially page 6, lines 2-9; page 14, lines 15-21; and page 23, lines 18-23	1-36
Y	WO 95 27044 A (BIOPTION AB ;LILJESTROEM PETER (SE); GAROFF HENRIK (SE)) 12 October 1995 cited in the application see the whole document, especially page 8, lines 12-22	1-36
A	WO 96 17072 A (VIAGENE INC) 6 June 1996 see the whole document	1-36

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

23 April 1999

Date of mailing of the international search report

03/05/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Mandl, B

INTERNATIONAL SEARCH REPORT

Inter. Patent Application No

PCT/CA 98/01064

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ZHOU X. ET AL.: "Self-replicating Semliki-Forest virus RNA as recombinant vaccine" VACCINE, vol. 12, no. 16, 1994, pages 1510-1514, XP002089524 cited in the application see the whole document	1-36
A	LILJESTROEM P. ET AL.: "A NEW GENERATION OF ANIMAL CELL EXPRESSION VECTORS BASED ON THE SEMLIKI FOREST VIRUS REPLICON" BIO/TECHNOLOGY, vol. 9, December 1991, pages 1356-1361, XP000616021 cited in the application see the whole document	1-36
E,L	WO 99 11808 A (CONNAUGHT LAB ;PARRINGTON MARK (CA)) 11 March 1999 cited in the application see the whole document	1-9,20, 23,24, 32,35,36

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 98/01064

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 20-30 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 98/01064

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9640945 A	19-12-1996	AU 695527 B	13-08-1998
		AU 6117696 A	30-12-1996
		CA 2223610 A	19-12-1996
		EP 0832253 A	01-04-1998
		US 5843913 A	01-12-1998
		US 5880104 A	09-03-1999
WO 9527044 A	12-10-1995	AU 699384 B	03-12-1998
		AU 2155795 A	23-10-1995
		CA 2184261 A	12-10-1995
		EP 0753053 A	15-01-1997
		FI 963860 A	27-09-1996
		JP 9511143 T	11-11-1997
WO 9617072 A	06-06-1996	AU 4594996 A	19-06-1996
		EP 0797679 A	01-10-1997
		US 5814482 A	29-09-1998
		US 5843723 A	01-12-1998
		US 5789245 A	04-08-1998
WO 9911808 A	11-03-1999	NONE	